Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Keros Therapeutics, Inc. on June 1, 2021. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Lexington, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected three nominees to serve until the 2024 Annual Meeting.
- Jasbir Seehra, Ph.D.: 16,991,741 votes for; 1,753,223 votes withheld.
- Nima Farzan: 16,514,159 votes for; 2,230,805 votes withheld.
- Julius Knowles: 16,325,440 votes for; 2,419,524 votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders approved the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 19,983,747
- Votes Against: 416
- Votes Abstain: 101
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 19, 2021, for detailed background on the director nominees and auditor selection.
- Confirm the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Review subsequent filings for the company's financial performance, as this 8-K contains no financial data.